Memory Disorders Clinical Trials

Stanford Memory Disorders Clinical Trials

Active, recruiting:

Sponsor: Eisai and Biogen (Clarity AD) 
Intervention
: BAN2401 (Monoclonal antibody binding to amyloid)
Indication
: MCI
Clinicaltrials.gov identifier: 
NCT03887455
PI: Sharon Sha, MD
Contact: Viktoriya Bourakova, viktoriya.bourakova@stanford.edu
Inclusion criteria:

·       MMSE score >=22 at Screening
·       CDR (global) 0.5 or 1
·       Age 50-90
·       Stable AD meds for > 3 months

Active, not recruiting:

Sponsor: Genentech (Lauriet Study)
Intervention
: RO7105705 (Monoclonal antibody binding to tau)
Indication
: Moderate AD
Clinicaltrials.gov identifier: NCT03828747
PI
: Sharon Sha, MD
Contact: 
Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Biogen (Tango Study)
Intervention
: BIIB092 (Monoclonal antibody binding to tau)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier: 
NCT03352557
PI
: Sharon Sha, MD
Contact:
 Viktoriya Bourakova, viktoriya.bourakova@stanford.edu

Sponsor: Genentech (Tauriel Study)
Intervention
: RO7105705 (Monoclonal antibody binding to tau)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier: 
NCT03289143
PI
: Sharon Sha, MD
Contact:
 Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Alzheimer's Disease Cooperative Study (PeaceAD Study)
Intervention
: Prazosin
Indication
: Probable or possible AD and disruptive agitation
Clinicaltrials.gov identifier: 
NCT03710642
PI
: Victor Henderson, MD and Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Sponsor: Cortexyme (Gain Study) 
Intervention
: COR388 (Gingipain inhibitor) 
Indication
: Mild to Moderate AD
Clinicaltrials.gov identifier: 
NCT03823404
PI
: Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Completing, not recruiting:

Sponsor: Novartis (Generations II Study)
Intervention:
 CNP520 (Active BACE-1 Inhibitor)
Target Population:
 Cognitively Unimpaired APOEHomozygotes or Amyloid Positive Heterozygotes
Clinicaltrials.gov identifier: 
NCT03131453
PI
: Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Sponsor: Novartis (Generations I Study)
Intervention:
 CAD106 (Induces Active Antibody without activating Aβ-reactive T cells) and CNP520 (BACE-1 Inhibitor)
Target Population:
 Cognitively Unimpaired APOEHomozygotes
Clinicaltrials.gov identifier: 
NCT02565511
PI
: Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Upcoming: (Recruiting by invitation only: participants who were previously enrolled in aducanumab trials) 

Sponsor: Biogen (Embark Study)
Intervention
: Aducanumab (Monoclonal antibody binding to amyloid)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier: 
NCT04241068
PI
: Sharon Sha, MD
Contact:
 Jenn Gaudioso, jenn.gaudioso@stanford.edu

Clinical trials contacts

memoryresearch@stanford.edu
(650) 724-8736

Sharon Sha, MD, MS
Clinical Assistant Professor, Neurology & Neurological Sciences
Director, Memory Disorders Clinical Trials
ssha1@stanford.edu
(650) 723-5072